OBJ Limited (ASX: OBJ) is pleased to announce the signing of an Evaluation Agreement
with GlaxoSmithKline Consumer Healthcare (GSK). GSK has granted permission to the
Company to release the following statement:
OBJ Limited wishes to advise that it has entered into a short term evaluation
agreement with GlaxoSmithKline Consumer Healthcare (GSK).
The Evaluation Agreement involves an evaluation of OBJs ETP technology in a
non‐prescription consumer healthcare application.
OBJ and GSK have worked together on three previous occasions and the current
Agreement is a continuation of that relationship.
- Forums
- ASX - By Stock
- WFL
- pre-open
pre-open, page-3
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable